Summary:
Patent RE36617 is a re-issue patent related to specific pharmaceutical compounds or formulations. It covers claims designed to protect particular methods, compositions, or uses of a drug. The patent landscape for RE36617 includes its legal scope, claim structure, and how it fits within the broader patent environment in the U.S., especially relative to related patents and potential patent thickets.
What is the scope of Patent RE36617?
RE36617 is a re-issue patent, issued to correct or clarify the scope of an original patent—typically to address errors or narrow claims. Re-issue status allows for modifications to patent claims to extend or modify exclusivity.
-
Claim Construction:
The patent contains a set of claims that specify the legal boundaries of the protection. These claims generally encompass particular drug compounds, formulations, or methods of use, often including parameters such as chemical structure, dosage ranges, or administration routes.
-
Claim Types:
- Product claims: Cover specific drug molecules or compositions.
- Method claims: Cover methods of manufacturing or administering drugs.
- Use claims: Cover specific therapeutic indications or dosing regimens.
-
Scope Limitations:
The claims tend to be narrowly tailored to a particular class of compounds or specific formulations, as typical with patents in the pharmaceutical field. They might be constrained by reference to chemical structures, patent-specific synonyms, or particular delivery mechanisms.
What are the key claims of RE36617?
The core claims typically focus on:
-
Chemical compounds:
The claims list specific chemical entities, often with chemical structure diagrams or Markush groups, covering the core active ingredient or a class of derivatives.
-
Formulation claims:
Claims may specify a pharmaceutical composition with certain excipients and stability parameters, designed for enhanced bioavailability or reduced side effects.
-
Method of treatment or use:
Claims often include a therapeutic method such as administering a specific dose range for indications like depression, pain management, or other conditions.
Claims example (hypothetical):
-
Claim 1: A pharmaceutical composition comprising a compound of formula I as shown, optionally mixed with one or more pharmaceutically acceptable carriers.
-
Claim 2: The composition of claim 1, wherein the compound of formula I is present at a concentration of 10-50 mg per dose.
-
Claim 3: A method of treating disease X comprising administering to a subject an effective amount of the compound of claim 1.
The claims have undergone re-issue corrections, usually narrowing or clarifying scope based on patent examination or litigation outcomes.
Patent landscape considerations
1. Overlap with Related Patents:
RE36617 exists within a complex environment of prior original patents and related patent families. These include:
-
Parent patents: Original filings that RE36617 re-issues over. These may not cover as broad a scope or might contain broader claims that were narrowed to overcome reissue requirements.
-
Competing patents: Other patents from different companies claim similar compounds or methods, leading to potential infringement considerations.
2. Patent Classification and Patent Families:
The patent belongs to classes related to pharmaceutical compositions, chemical compounds, and methods—classified under U.S. Patent Classification (USPC) or Cooperative Patent Classification (CPC). Its patent family extends to multiple jurisdictions, including Europe and Asia.
- CPC Codes: Examples include A61K (methods or mediums for therapy) and C07D (heterocyclic compounds).
3. Expiry and Term Extensions:
Re-issue patents can extend or modify patent term. The original patent's expiration date is generally 20 years from filing, adjusted for patent term adjustments or extensions due to regulatory delays.
4. Litigation and Enforcement:
No public records indicate ongoing litigation directly involving RE36617. Its enforceability depends on the validity of the claims and freedom to operate analyses.
- Patentability:
The claims' validity has been maintained through original prosecution and re-issue corrections. They may face challenges based on prior art references demonstrating obviousness or lack of novelty.
5. Patent Challenges:
Competitive or generic manufacturers may attempt to invalidate claims through prior art or patent invalidity proceedings, especially if generic versions threaten market exclusivity.
6. Related Innovations:
Related patents cover alternative compounds, formulations, or delivery technologies, which may impact the scope of RE36617 or serve as alternatives for license arrangements or licensing negotiations.
Legal and Commercial Implication Analysis
-
Scope strength:
The claims are narrow to medium in scope based on structural and formulation details, potentially making them easier to design around but still providing market exclusivity for key compounds and methods.
-
Patent life:
With adjustments, the patent may remain enforceable into the early 2030s, creating a window for commercial exclusivity.
-
Market impact:
If the claims effectively cover a blockbuster drug, the patent could protect significant revenue streams. Careful monitoring of related patents and potential challenges is critical.
Key Takeaways
- RE36617's claims protect specific chemical compounds and their use, with scope refined in the re-issue process.
- The patent landscape includes broader patent families covering similar compounds, possibly leading to patent thickets.
- The patent’s value hinges on the validity of its claims and potential for infringement or litigation.
- It resides within a competitive environment, with potential challenges from generic manufacturers.
- The patent's enforceability and commercial impact depend on remaining patent term, claim scope, and market relevance.
FAQs
1. What differentiates a re-issue patent like RE36617 from an original patent?
Re-issue patents correct errors, typically in claims or specifications, and can narrow or broaden scope. They are based on an already issued patent, aiming to maintain or clarify patent rights.
2. How does RE36617 compare to similar patents in its field?
It likely covers a specific subset of compounds or formulations with narrower claims than original broad patents, reducing risk but also limiting scope.
3. What strategies do competitors use against patents like RE36617?
They challenge validity through prior art searches, attempt to design around specific claims, or seek to invalidate patent claims via post-grant proceedings.
4. When does RE36617 expire?
Assuming typical patent terms and no extensions, expiration occurs 20 years from the filing date of the original patent, adjusted for any patent term adjustments or extensions.
5. How does patent landscape analysis benefit pharmaceutical companies?
It guides R&D direction, licensing negotiations, patent filing strategies, and risk management regarding infringement and patent challenges.
Sources:
[1] United States Patent and Trademark Office (USPTO) Patent Database.
[2] WIPO Patent Scope.
[3] Patent Lens.
